Oxford BioMedica Plc
Immunotherapy Company
Website
www.oxfordbiomedica.co.uk
Contact Name
Prof. Alan Kingsman
Company Position
Chief Executive Officer
Contact Email
enquiries@oxfordbiomedica.co.uk
Contact Address
Medawar Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
UK
Contact Phone
+44 1865 783000
Latest News
25th March 2008
Oxford BioMedica, a leading gene therapy company, announces encouraging new data from its first Phase II trial of TroVax in prostate cancer.
Read this article
More News
20th February 2008
Oxford BioMedica announced today that the independent DSMB for the Phase III TRIST study of TroVax in renal cancer has completed its third planned interim analysis and recommended that the study continue without modification.
Read this article
28th March 2007
Oxford BioMedica and Sanofi-aventis have entered into an exclusive global licensing agreement to develop and commercialise Trovax®.
Read this article
12th March 2007
Oxford BioMedica, the leading gene therapy company, has entered into an agreement to acquire Oxxon Therapeutics.
Read this article
On the 12th of March 2007 Oxford BioMedica Plc acquired Oxxon Therapeutics, a privately held biotechnology company, in an all-share deal valued at £16 million.
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel therapeutic vaccines and gene-based therapies with a focus on the areas of oncology and neurotherapy. Oxford BioMedica's lead product, TroVax® is a cancer immunotherapy that has potential application in most solid tumour types, and which has been licensed to sanofi-aventis for global development and commercialisation.
Oxxon focused on the development of novel therapeutic vaccines for the treatment of cancer and infectious diseases. The acquisition provides Oxford BioMedica with a complementary cancer immunotherapy product candidate, Hi-8® MEL, which has completed a Phase II trial in melanoma, the only solid tumour that cannot be treated with TroVax. Oxford BioMedica has also gained Oxxon's other therapeutic programmes in infectious diseases, including hepatitis B and HIV. In addition, the acquisition strengthens Oxford BioMedica's intellectual property position in immunotherapy and gene-based medicines.
For more information visit www.oxfordbiomedica.co.uk
